Literature DB >> 10072445

Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.

L Chen1, W Lu, S Agrawal, W Zhou, R Zhang, J Chen.   

Abstract

BACKGROUND: The MDM2 oncogene functions as a negative feedback regulator of the p53 tumor suppressor. Abnormal expression of MDM2 in tumors may attenuate the p53-mediated growth arrest and apoptosis response, resulting in increased cell proliferation and resistance to chemotherapy.
MATERIALS AND METHODS: We have developed phosphorothioate antisense oligodeoxynucleotides optimized for inhibition of MDM2 expression and investigated the role of MDM2 in a large panel of tumor cell lines.
RESULTS: Inhibition of MDM2 expression in 15 tumor types containing wild-type p53 results in a significant induction of nuclear p53 accumulation. The increase in p53 level is due to prolonged half-life and is associated with an increase in p53 transcriptional activity, growth inhibition, or apoptosis. Inhibition of MDM2 expression is also sufficient to induce nuclear p53 accumulation in several cell lines with cytoplasmic p53.
CONCLUSIONS: The MDM2 negative feedback loop is important for maintenance of p53 at a low level by promoting p53 degradation. Nuclear export and degradation by MDM2 may contribute to the p53 nuclear exclusion phenotype. Inhibition of MDM2 expression can effectively activate p53 in most tumor types, including those without MDM2 overexpression, and may have broad anti-tumor potential.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072445      PMCID: PMC2230374     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  37 in total

1.  Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis.

Authors:  E Gottlieb; R Haffner; A King; G Asher; P Gruss; P Lonai; M Oren
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

2.  Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.

Authors:  E A Komarova; M V Chernov; R Franks; K Wang; G Armin; C R Zelnick; D M Chin; S S Bacus; G R Stark; A V Gudkov
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

3.  Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

Authors:  A Böttger; V Böttger; A Sparks; W L Liu; S F Howard; D P Lane
Journal:  Curr Biol       Date:  1997-11-01       Impact factor: 10.834

Review 4.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

5.  p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.

Authors:  C A Midgley; D P Lane
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

6.  Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage.

Authors:  U M Moll; A G Ostermeyer; R Haladay; B Winkfield; M Frazier; G Zambetti
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

7.  The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization.

Authors:  S C Goldman; C Y Chen; T J Lansing; T M Gilmer; M B Kastan
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

8.  Regulation of p53 stability by Mdm2.

Authors:  M H Kubbutat; S N Jones; K H Vousden
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

9.  Mdm2 promotes the rapid degradation of p53.

Authors:  Y Haupt; R Maya; A Kazaz; M Oren
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

10.  DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.

Authors:  S Y Shieh; M Ikeda; Y Taya; C Prives
Journal:  Cell       Date:  1997-10-31       Impact factor: 41.582

View more
  15 in total

1.  ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.

Authors:  Lihong Chen; Daniele M Gilkes; Yu Pan; William S Lane; Jiandong Chen
Journal:  EMBO J       Date:  2005-09-15       Impact factor: 11.598

2.  The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress.

Authors:  S M Mendrysa; M E Perry
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 3.  Strategies for manipulating the p53 pathway in the treatment of human cancer.

Authors:  T R Hupp; D P Lane; K L Ball
Journal:  Biochem J       Date:  2000-11-15       Impact factor: 3.857

4.  Expression of MDM2 protein and mRNA in condyloma acuminata.

Authors:  Li Zhu; Yating Tu; Changzheng Huang; Houjun Liu; Aiping Feng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

5.  Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.

Authors:  Takehiko Shiraishi; Jonhard Eysturskarth; Peter E Nielsen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

6.  Nuclear to cytoplasmic shift of p33(ING1b) protein from normal oral mucosa to oral squamous cell carcinoma in relation to clinicopathological variables.

Authors:  Jin-Ting Zhang; Da-Wei Wang; Qing-Xing Li; Zhen-Long Zhu; Ming-Wei Wang; Dong-Sheng Cui; Yan-Hong Yang; Yu-Xin Gu; Xiao-Feng Sun
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-06       Impact factor: 4.553

7.  Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminoacridine-PNA (peptide nucleic acid) conjugates.

Authors:  Takehiko Shiraishi; Peter E Nielsen
Journal:  Nucleic Acids Res       Date:  2004-09-15       Impact factor: 16.971

8.  Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53.

Authors:  Jason A Clement; Jirouta Kitagaki; Yili Yang; Carrie J Saucedo; Barry R O'Keefe; Allan M Weissman; Tawnya C McKee; James B McMahon
Journal:  Bioorg Med Chem       Date:  2008-10-14       Impact factor: 3.641

9.  Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.

Authors:  Ana P D Ano Bom; Luciana P Rangel; Danielly C F Costa; Guilherme A P de Oliveira; Daniel Sanches; Carolina A Braga; Lisandra M Gava; Carlos H I Ramos; Ana O T Cepeda; Ana C Stumbo; Claudia V De Moura Gallo; Yraima Cordeiro; Jerson L Silva
Journal:  J Biol Chem       Date:  2012-06-19       Impact factor: 5.157

10.  Concurrent overexpression of serum p53 mutation related with Helicobacter pylori infection.

Authors:  Juan-Bosco Lopez-Saez; Victoria Gómez-Biondi; Germán Santamaría-Rodriguez; Margarita Dominguez-Villar; Antonio Amaya-Vidal; Antonio Lorenzo-Peñuelas; Avelino Senra-Varela
Journal:  J Exp Clin Cancer Res       Date:  2010-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.